Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • x Allergen immunotherapy (13)
  • x Pediatrics (1)
  • Systems medicine (1)
Poster available until
Poster categories
  • Thematic Poster Session (13)
keywords
Session Reference
  • L-TPS02 (1)
  • L-TPS03 (9)
  • L-TPS06 (1)
  • L-TPS07 (1)
  • L-TPS08 (1)
  • L-TPS09 (2)
  • L-TPS10 (3)
  • L-TPS11 (12)
  • L-TPS12 (1)
  • L-TPS13 (2)
  • L-TPS14 (1)
  • L-TPS16 (1)
  • x L-TPS17 (13)
  • L-TPS18 (9)
  • L-TPS20 (3)
  • L-TPS21 (1)
  • TPS01 (1)
  • TPS02 (1)
  • TPS05 (5)
  • TPS08 (8)
  • TPS09 (9)
  • TPS10 (9)
  • TPS11 (4)
  • TPS14 (2)
  • TPS15 (3)
  • TPS16 (2)
  • TPS19 (1)
  • TPS20 (7)
  • TPS25 (1)
  • TPS27 (1)
  • TPS28 (8)
  • TPS32 (14)
  • TPS33 (10)
  • TPS34 (9)
  • TPS39 (2)
  • TPS41 (2)
  • TPS44 (3)
  • TPS51 (2)
  • TPS52 (2)
  • TPS53 (1)
  • TPS54 (1)
  • TPS56 (10)
  • TPS58 (1)
  • TPS63 (3)
  • TPS64 (1)
  • TPS68 (8)
13 results
Thumbnail

D3.178 - Efficacy of Index of reactivity (IR) liquid sublingual immunotherapy in allergic rhinoconjunctivitis: A systematic review and meta-analysis of randomised studies

Thumbnail

D3.179 - Safety of 300IR liquid sublingual immunotherapy of cat allergen extract for respiratory allergy to cat dander: a post-marketing experience

Thumbnail

D3.180 - Good patient adherence to sublingual immunotherapy for allergic rhinitis can be achieved, when ENT-physicians collaborate with pharmacies in a straightforward adherence programme

Thumbnail

D3.182 - Health Economic Evaluation of 5-Grass Pollen Sublingual ImmunotherapyTablets for Grass Pollen-Induced Allergic Rhinitis in Finland, Norway and Sweden

Thumbnail

D3.183 - Reduction in Healthcare Resource Utilization in patients treated with 300 IR liquid SLIT: Real-World Evidence from Spain and Italy

Thumbnail

D3.184 - Treatment with the 300 IR house dust mite sublingual tablet is safe and well tolerated in adults and adolescents in a real-world data setting – results of a non-interventional post authorization safety study

Thumbnail

D3.185 - The 300 IR house dust mite sublingual tablet is effective and well tolerated in patients with allergic rhinoconjunctivitis and concomitant allergic asthma in a real-world data setting

Thumbnail

D3.186 - A new allergenic protein in holm oak (Quercus ilex) pollen: Glutathione-S-transferase

Thumbnail

D3.187 - Adverse reactions to sublingual immunotherapy with carbamylated allergoids of different sources in clinical studies

Thumbnail

D3.188 - Comparison of Completion Rates and Factors Influencing Discontinuation in Paediatric Allergen Immunotherapy: A Five-Year Single-Center Experience

Thumbnail

D3.189 - Adverse reactions to subcutaneous immunotherapy for mite in children and adolescents in a tertiary care center

Thumbnail

D3.190 - Follow up cases of subcutaneous allergen Immunotherapy in respiratory allergic diseases continuing for 10-30years “A Real life experience of 14 cases”

Thumbnail

D3.191 - Case report: Acute systemic reactions to sublingual immunotherapy for tree pollen

Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM